With the rapid pace of immunologic research, it is more important than ever for readers to understand rational immunodiagnosis, immunopro-phylaxis, and immunotherapy. This column is intended to help you ensure proper immunologic drug use in your practice.
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control and Prevention. Recommended childhood immunization schedule—United States, 1998. MMWR.1998;47: 8–12.
2.
Advisory Committee on Immunization Practices.General recommendations on immunization. MMWR.1994; 43(RR-1): 1–38.
3.
American College of Physicians.Guide for Adult Immunization.3rd ed.Philadelphia, PA: American College of Physicians; 1994.
4.
GrabensteinJ.D.ImmunoFacts: Vaccines and Immunologic Drugs.St. Louis, MO: Facts and Comparisons, Inc.; February 1999.
5.
Canadian National Advisory Committee on Immunization. Canadian Immunization Guide.4th ed.Ottawa, Ontario: Ministry of National Health and Welfare; 1993.
6.
PeterG., ed. 1997 Red Book: Report of the Committee on Infectious Diseases.24th ed.Elk Grove Village, IL: American Academy of Pediatrics; 1997.
7.
Advisory Committee on Immunization Practices.Pneumococcal polysaccharide vaccine. MMWR.1997; 46(RR-8): 1–24.
8.
Advisory Committee on Immunization Practices.Prevention and control of influenza. MMWR.1998; 47(RR-6): 1–25.
9.
Advisory Committee on Immunization Practices.Immunization of health-care workers. MMWR.1997; 46(RR-18): 1–42.
10.
Centers for Disease Control and Prevention. Health Information for International Travel, 1996-97.Washington, DC: Government Printing Office; 1997.
11.
Advisory Committee on Immunization Practices.Use of vaccines and immune globulins in persons with altered immuno-competence. MMWR.1993; 42(RR-4): 1–18.
12.
GrabensteinJ.D.Vaccine misconceptions and inappropriate contraindications lead to preventable illness and death. Hosp Pharm.1998; 331557–1567.
13.
GrabensteinJ.D., HaytonB.D.Pharma-coepidemiologic program for identifying patients in need of vaccination. Am J Hosp Pharm.1990; 47: 1774–1781.
14.
GrabensteinJ.D.Immunization Delivery: A Complete Guide.St. Louis, MO: Facts and Comparisons, Inc.; 1997.
15.
BerenguerM., WrightT.L.Are HCV-infected individuals candidates for hepatitis A vaccine?Lancet.1998; 351: 924–925.
16.
Advisory Committee on Immunization Practices.Prevention of hepatitis A through active or passive immunization. MMWR.1996; 45(RR-15): 1–30.
HibberdP.L., RubinR.H.Approach to immunization in the immunosuppressed host. Infect Dis Clin N Amer.1990; 4: 123–142.
19.
Advisory Committee on Immunization Practices.Update: Vaccine side effects, adverse reactions, contraindications, and precautions. MMWR.1996; 45(RR-12): 1–35, errata 227.
20.
AmbrosinoD.M., MolrineD.C.Critical appraisal of immunization strategies for prevention of infection in the compromised host. Hemat/Oncol Clin N Amer.1993; 7: 1027–1050.
21.
US Preventive Services Task Force.Guide to Clinical Preventive Services.2nd ed.Baltimore, MD: Williams & Wilkins; 1996.
22.
Advisory Committee on Immunization Practices.Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. MMWR.1997; 46(RR-3): 1–25, errata 183.
23.
Advisory Committee on Immunization Practices.The role of BCG vaccine in the prevention and control of tuberculosis in the United States: A joint statement by the Advisory Council for the Elimination of Tuberculosis and the ACIP. MMWR.1996; 45(RR-4): 1–18.
24.
Advisory Committee on Immunization Practices.Measles, mumps, and rubella—Vaccine use and strategies for elimination of measles, rubella, and congenital
